Modes of resistance to anti-angiogenic therapy
Explore this paper's citation graph
Summary
Emerging data support a proposition that two modes of unconventional resistance underlieAngiogenesis inhibitors targeting the vascular endothelial growth factor signalling pathways are affording demonstrable therapeutic efficacy in mouse models of cancer and in an increasing number of human cancers.
- Type
- review
- Published
- 2008-08-01
- Cited by
- 2,912
- References
- 102
- Access
- Open access
- OpenAlex
- https://openalex.org/W2017322644
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:19543665
Keywords
Angiogenesis, Blockade, Cancer research, Adaptation (eye), Medicine
References
- Can tumor angiogenesis be inhibited without resistance?
- A double blind phase II study of BIBF 1,120 in patients suffering from relapsed advanced non-small cell lung cancer (NSCLC)
- Antiangiogenic therapy for cancer: current and emerging concepts.
- Possible Mechanisms of Acquired Resistance to Anti-angiogenic Drugs: Implications for the Use of Combination Therapy Approaches
- Control of angiogenesis by the pericyte: molecular mechanisms and significance.
- Tumour-educated macrophages promote tumour progression and metastasis
- Inflammation Induces Myeloid-Derived Suppressor Cells that Facilitate Tumor Progression1
- Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2.
- A cancer therapy resistant to resistance
- Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenes
- Pegaptanib for neovascular age-related macular degeneration.
- Emerging roles of targeted small molecule protein-tyrosine kinase inhibitors in cancer therapy.
- Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1+ stem cells from bone-marrow microenvironment
- What brings pericytes to tumor vessels?
- Inhibiting angiogenesis and tumorigenesis by a synthetic molecule that blocks binding of both VEGF and PDGF to their receptors
- The Delta paradox: DLL4 blockade leads to more tumour vessels but less tumour growth
- Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors.
- Differential diagnosis of pancreatic tumors using ultrasound contrast imaging
- Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1
- A quantitative analysis of kinase inhibitor selectivity
Cited by
- La resistencia adaptativa a terapias antiangiogénicas en un modelo murino de cáncer
- QUANTIFICATION OF FACTORS GOVERNING DRUG RELEASE KINETICS FROM NANOPARTICLES: A COMBINED EXPERIMENTAL AND MECHANISTIC MODELING APPROACH
- Ligand-Directed AAVP to Deliver a Therapeutic Transgene to Neuroendocrine Tumors of the Pancreas
- Studying drug resistance using genetically engineered mouse models for breast cancer.
- Disparate Companions: Tissue Engineering Meets Cancer Research
- Adrenomedullin expression and regulation in human glioblastoma, cultured human glioblastoma cell lines and pilocytic astrocytoma.
- Decrease in VEGF Expression Induces Intussusceptive Vascular Pruning
- Angiogenesis: a target in solid tumors, also in leukemia?
- Adrenomedullin interacts with VEGF in endometrial cancer and has varied modulation in tumours of different grades.
- Overcoming disappointing results with antiangiogenic therapy by targeting hypoxia
- Development and characterization of a high-throughput in vitro cord formation model insensitive to VEGF inhibition
- Molecular targeted therapy for hepatocellular carcinoma: current and future.
- Antiangiogenesis beyond VEGF inhibition: a journey from antiangiogenic single-target to broad-spectrum agents.
- Intratumoral Vascular Shunting: Biomarker of Clinical Outcome and Source of Circulating Tumor Cells?
- Detection of p53 mutations in proliferating vascular cells in glioblastoma multiforme.
- Delta-like ligand 4-targeted nanomedicine for antiangiogenic cancer therapy.
- Aggressive primary cutaneous B‐cell lymphomas show increased Angiopoietin‐2‐induced angiogenesis
- Glioblastoma vasculogenic mimicry: signaling pathways progression and potential anti-angiogenesis targets
- TRPV4 channel activation selectively inhibits tumor endothelial cell proliferation
- Dual metronomic chemotherapy with nab-paclitaxel and topotecan has potent anti-angiogenic activity in ovarian cancer
Related papers
- Expression of total vascular endothelial growth factor (VEGF) and inhibitory isoforms of VEGF in head and neck squamous cell carcinoma
- Serum vascular endothelial growth factor (VEGF), soluble VEGF receptor-1 (sVEGFR-1) and sVEGFR-2 in systemic sclerosis patients: Relation to clinical manifestations and capillaroscopy findings
- The Effect of VEGF (Vascular endothelial growth factor) on Endothelial Cells in Pathogenesis of Preeclampsia
- The effect of AD-VEGF-siRNA on the expression of vascular endothelial growth factor in osteosarcoma-bearing nude mice
- Vascular Endothelial Growth Factor (VEGF) In Aqueous Humor: Prognostic Factor In Uveal Melanoma
- Comparison of Serum Concentrations of Bevacizumab and Vascular Endothelial Growth Factor (VEGF) Levels in Laser and Bevacizumab Treated ROP Patients
- Application of Vascular Endothelial Growth Factor in Spinal Cord Injury(review)
- Inhibiting effect of vascular endothelial growth factor （VEGF） antisense oligodeoxynucleotides on VEGF expression in U937 cells